EGFR and non-small cell lung carcinoma: Two phase II trials have assessed the effect of afatinib as first-line treatment of fit elderly patients with EGFR mutant NSCLC, with both demonstrating a PFS benefit compared to historical control [10, 11], and there are promising outcomes in real-world populations [12–14].